Retroviral Marking and Transplantation of Rhesus Hematopoietic Cells by Nonmyeloablative Conditioning
- 20 July 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (11) , 1783-1790
- https://doi.org/10.1089/10430349950017464
Abstract
The ability to engraft significant numbers of genetically modified hematopoietic stem and progenitor cells without the requirement for fully myeloablative conditioning therapy is a highly desirable goal for the treatment of many nonmalignant hematologic disorders. The aims of this study were to examine, in nonhuman primates (rhesus), (1) the effects of pretreatment of host animals with cytokines (G-CSF and SCF), i.e., before nonmyeloablative irradiation, on the degree and duration of neo gene marking of circulating leukocytes after autologous cell reinfusion and (2) to compare transduction of primitive hematopoietic target cells in the presence of our standard transduction cytokine combination of IL-3, IL-6, and stem cell factor (SCF) and in the presence of an alternative combination containing SCF, G-CSF, and the thrombopoietin analog MGDF. Cytokine-mobilized rhesus peripheral blood progenitor/stem cells (PBSCs) were enriched for CD34+ cells and transduced with neo vectors (either G1Na or LNL6) for 96 hr in cultures containing rhIL-3, rhIL-6, and rhSCF or MGDF, rhSCF, and rhG-CSF and cryopreserved. Four animals underwent minimal myeloablative conditioning with 500 cGy irradiation with or without pretreatment with SCF and G-CSF, followed by reinfusion of the cryopreserved cells on the subsequent day. Neutrophil nadirs (<500/mm3) were 0-3 days in duration; there were no significant periods of severe thrombocytopenia. Marking of circulating granulocytes and mononuclear cells was extensive and durable in all animals (exceeding 12% in the mononuclear cells of one animal) and persisted beyond the final sampling time in all animals (up to 33 weeks). No difference in extent or duration of marking was attributable to either cytokine presensitization of recipients prior to irradiation, or to the substitution of MDGF and G-CSF for IL-3 and IL-6 during transduction.Keywords
This publication has 42 references indexed in Scilit:
- Retroviral Transfer of the Glucocerebrosidase Gene into CD34+ Cells from Patients with Gaucher Disease: In Vivo Detection of Transduced Cells without MyeloablationHuman Gene Therapy, 1998
- Evaluation of a Cytokine Combination Including Thrombopoietin for Improved Transduction of a Retroviral Gene into G‐CSF‐Mobilized CD34 + Human Blood CellsThe International Journal of Cell Cloning, 1997
- Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor.Proceedings of the National Academy of Sciences, 1996
- Gene Transfer into Hematopoietic Stem Cells of Nonhuman PrimatesHuman Gene Therapy, 1996
- Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells.Proceedings of the National Academy of Sciences, 1996
- GENE TRANSFER TO HEMATOPOIETIC STEM CELLS: Implications for Gene Therapy of Human DiseaseAnnual Review of Medicine, 1996
- Gene marking and gene therapy directed at primary hematopoietic cellsCurrent Opinion in Hematology, 1996
- Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brainNature Genetics, 1994
- Negative regulation of early B lymphopoiesis by interleukin 3 and interleukin 1 alpha.Proceedings of the National Academy of Sciences, 1994
- Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patientsThe Lancet, 1993